Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A drug for testicular cancer that cost an estimated $56 million to develop led to a sharp increase in survival rate and an annual return of $166 million in treatment…  
  • The 5-year survival rate for cancer has gone up 40 percent in the last 40 years.  
  • An experimental drug has been found to extend the lives of kidney patients by about 3.5 months–from 7 to just under 11. It has also been shown to delay…  
  • FDA approved cancer advances
     
  • If the 1 million surgical breast biopsies performed annually were instead performed using image-guided needle core biopsy, the total savings could be $1.6 billion a year.